SynDevRx, Inc. Press Releases - EIN Presswire - Press Release Distribution Service

Published on February 19, 2026 - 14:30 GMT

SynDevRx Publishes Data On Evexomostat Establishing New Metabo-Oncology Therapeutic Modality

Frontiers in Oncology publication positions metabo-oncology as a differentiated platform for pharma and a novel, risk-mitigated opportunity for investors. CAMBRIDGE, MA, UNITED STATES, February 19, 2026 /⁨EINPresswire.com⁩/ -- SynDevRx, Inc., a clinical- …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on December 2, 2025 - 15:00 GMT

Memorial Sloan Kettering to Present Clinical Data from The ARETHA-1 Trial of SynDevRx’s Evexomostat in mTNBC at SABCS

Safety Run-in Cohort Results Show Anti-tumor Activity Plus Systemic Metabolic Improvements with Evexomostat Plus Eribulin in Late-line Metastatic TNBC Patients NEW YORK, NY, UNITED STATES, December 2, 2025 /⁨EINPresswire.com⁩/ -- Memorial Sloan Kettering …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on January 9, 2025 - 12:12 GMT

$1.2M Grant Awarded for Groundbreaking Prostate Cancer Research on SynDevRx MetAP2 Inhibitor 'Evexomostat'

Award follows extensive pre-clinical, single agent activity data generated by Prof. Colleen Nelson’s lab at QUT in ‘Aggressive Variant’ prostate cancer models CAMBRIDGE, MA, UNITED STATES, January 9, 2025 /⁨EINPresswire.com⁩/ -- Cambridge, MA (USA) and …

Distribution channels: Healthcare & Pharmaceuticals Industry ...